Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Early Signals and Limits in Health Actuaries Data GLP-1 medications pose a familiar yet unusually complex challenge for health actuaries: a high-cost innovation with promising long-term clinical benefits, but limited actuarial credibility in the near term
Youll begin seeing results from your hard work
Abstract Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough therapies for type 2 diabetes mellitus (T2DM)
But true receptor downregulation through lysosomal degradation requires the cell to synthesize entirely new receptors, a process that takes considerably longer
Over time, this can lead to dehydration that worsens medication side effects, slows your metabolism, and reduces the results you are working toward
US$ 29.08
US$ 27.39
US$ 23.46
US$ 22.44
US$ 22.37
US$ 24.64
US$ 22.73
US$ 24.65
US$ 24.23
